On the stock market since 2021, it operates in the world of health and science. It has 216 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
An average decline of 22% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $17.9M a year. A small number, but proof the product has real buyers.
There is $33.6M in the vault; even if every debt were paid off, $24.3M would remain.
Over the last 12 months, company executives reported 45 buys and 20 sells. Management buying with its own money is usually read as a good sign.
A loss of $3.7M against $17.9M in annual sales. And on top of that, sales fell from the year before.
The sales tempo runs behind the sector. Council score: 2/10.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
On our five-subject report card, UPC sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: UPC is a high-risk stock — not yet profitable, and its future rides on its product catching on.